Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys CYTK Stock
Representative Gilbert Ray Cisneros Jr. recently purchased shares of Cytokinetics valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Cytokinetics, Incorporated ($CYTK) stock on September 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $CYTK is down 6.5% after 1 week and down 5.6% to date (from the $65.64 close on Sep 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Cytokinetics, Incorporated ($CYTK) | Buy | Sep 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
CYTK
Cytokinetics, Incorporated
Key Points
- On September 29, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Cytokinetics, valued between $1,001 and $15,000.
- Cytokinetics shares recently traded around $62.66, and the company has a revenue of $67.7 million but reported a negative EPS of -$7.22.
- Cytokinetics has seen activity from other institutional investors, including Blackrock Inc. with 20,094,362 shares worth about $1.24 billion.
Get $CYTK trade alerts by text
We text you when insiders, Congress or big funds trade $CYTK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cytokinetics, Incorporated alert may contain errors. Disclosures
Representative Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Cytokinetics, Incorporated (CYTK) on September 29, 2026. The trade was valued between $1,001 and $15,000, according to a periodic transaction report filed under the STOCK Act on October 12, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Gilbert Ray Cisneros Jr.'s Cytokinetics Position
Cisneros's recent purchase is a notable addition to his portfolio, reflecting continued interest in the biotechnology sector. This is his first reported buy since June 5, 2026, when he purchased shares of The Cooper Companies.
Other Institutional Activity in Cytokinetics
Cytokinetics has also seen notable activity from other institutional investors. Blackrock Inc. increased its holdings by 3,546,259 shares, bringing its total to 20,094,362 shares worth about $1.24 billion. T. Rowe Price Investment Management, Inc. added 1,195,096 shares, totaling 18,718,498 shares valued at approximately $1.16 billion. Meanwhile, Vanguard Portfolio Management LLC grew its stake by 867,830 shares, ending with 6,711,799 shares valued at around $415.8 million.
Cytokinetics, Incorporated Stock Down 2.0%
As of October 16, 2026, Cytokinetics shares were recently trading around $62.66. This price comes as the company prepares for its next earnings report on November 5, 2026. The shares have faced volatility, reflecting broader market trends in the biotechnology sector.
Recent Earnings
Cytokinetics reported trailing-twelve-month revenue of $67.7 million but has not turned a profit, reflecting an EPS of -$7.22. The company is working on developing treatments aimed at debilitating diseases, which could influence future revenue growth.
Insider Buying and Selling at Cytokinetics, Incorporated
On September 15, 2026, Director Robert E. Landry sold 1,000 shares at an average price of $72.13, totaling about $72,130. Chief Executive Officer Robert I. Blum also sold 7,500 shares on September 28, 2026, at a price of $65.46, valued at approximately $490,950. These transactions occurred before Cisneros's recent purchase.
Analysts Set New Price Targets
Analysts have maintained positive outlooks for Cytokinetics. On August 7, 2026, RBC Capital maintained an "Outperform" rating with a price target of $112. Truist Securities followed suit on August 10, 2026, with a "Buy" rating and a target of $112. The consensus among analysts reflects a strong belief in the company's growth potential.
About Cytokinetics
Cytokinetics, Incorporated is a biopharmaceutical company based in South San Francisco, California. It focuses on developing treatments that activate or inhibit muscle function to address serious diseases. The company markets MYQORZO, a treatment for a specific heart condition, and is actively exploring other potential therapies.
Bottom Line
Looking ahead, investors will be watching for Cytokinetics' upcoming earnings report on November 5, 2026, as well as any further disclosures from Rep. Cisneros. His recent buy adds to his history of trading in the biotech space, following his earlier sale of shares in other companies.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $CYTK (Sep 29, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts